MARKET

DWTX

DWTX

Dogwood Therapeutics
NASDAQ
1.368
-0.012
-0.85%
Opening 10:36 07/21 EDT
OPEN
1.370
PREV CLOSE
1.380
HIGH
1.440
LOW
1.360
VOLUME
4.25K
TURNOVER
--
52 WEEK HIGH
9.50
52 WEEK LOW
1.280
MARKET CAP
46.02M
P/E (TTM)
-0.1291
1D
5D
1M
3M
1Y
5Y
1D
Dogwood enrolls first 200 patients in HAL-CINP trial
TipRanks · 1d ago
Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of Halneuron
Benzinga · 1d ago
Dogwood Therapeutics announces press release availability
PUBT · 1d ago
DOGWOOD ENROLLS FIRST 200 PATIENTS IN ONGOING HALNEURON® PHASE 2B CHEMOTHERAPY INDUCED NEUROPATHY TRIAL; TOP-LINE DATA EXPECTED IN FALL 2026
Reuters · 1d ago
Weekly Report: what happened at DWTX last week (0713-0717)?
Weekly Report · 1d ago
Weekly Report: what happened at DWTX last week (0706-0710)?
Weekly Report · 07/13 09:23
Weekly Report: what happened at DWTX last week (0629-0703)?
Weekly Report · 07/06 09:24
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC), Dogwood Therapeutics (DWTX) and Sanofi (OtherSNYNF)
TipRanks · 07/06 07:20
More
About DWTX
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

Webull offers Dogwood Therapeutics Inc stock information, including NASDAQ: DWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DWTX stock methods without spending real money on the virtual paper trading platform.